DOI:
10.1055/s-00000034
Klinische Pädiatrie
LinksClose Window
References
Vandyke K, Dewar AL, Diamond P et al.
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
J Bone Miner Res 2010;
25: 1759-1770
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.